American College of Allergy, Asthma and Immunology (ACAAI) Release: Allergists Addressing FDA Hearing Support Continued Availability of Asthma Medication, Encourage Patients with Questions to Contact Physicians

WASHINGTON--(BUSINESS WIRE)--The nation’s allergists urged a Joint FDA Advisory Committee meeting today to continue to make long-acting beta-2 agonists available for the treatment of moderate-to-severe asthma in appropriate patients.